Racial Disparity in Antibody Against A rare High Prevalence Antigen; (Anti-Inb) Article Swipe
M Abdelmonem
,
Nye Thane Ngo
,
W Cai
,
M Yunce
,
K Papakonstantino
,
C Jurado
,
Mrigender Virk
,
Juneyoung Lee
,
Sam S. Chang
,
S Yoshizuka
,
M Cabungan
·
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.1093/ajcp/aqad150.237
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.1093/ajcp/aqad150.237
Introduction/Objective Introduction: Ina antigen is very rare except in Iranian and Arab populations (10.6% and 11.8%, respectively). In 1973, Badkere et al. identified this antigen in about 3% of Indians from Bombay. Inb is a very high-prevalence antigen. It is prevalent in 99.9% of Caucasians and blacks, 96% of Indians and South Asians, and 90% of Iranians and Arabs. The Indian blood group system also has two other very high prevalence antigens: INFI and INJA. Indian blood group resides in CD44 glycoprotein that binds to hyaluronate of extracellular matrix. CD44 is an adhesion molecule in lymphocytes, monocytes, and other tumor cells, but its function in RBC is unknown. Ina and Inb are sensitive to proteolytic enzyme treatments and destroyed by disulfide bond-reducing agents 2-aminoethyl isothiouronium bromide (AET) and dithiothreitol (DTT). Methods/Case Report Case study: An 11-year-old female of South-East Indian descent with a history of intractable epilepsy was admitted for surgical treatment for epilepsy. Her antibody screen was positive, and her plasma reacted with all cells in PEG AHG except for the auto control. Ficin and DTT-treated cells weakened the reactivity. Suspecting a high-frequency antibody, the patient's plasma was tested against a series of cells in the rare donor cell inventory, including O Bombay cell and Inb-cell considering the patient's ethnicity. With Inb-negative cells, the plasma tested negative. All major alloantibodies from this rare donor cell were ruled out except for anti-C, anti-E, anti-K, and anti-S due to the availability of the rare cell. Results (if a Case Study enter NA) NA Conclusion Antigen Inb has a high prevalence in all populations. The rare phenotype In(b–) has been observed in approximately 2 of 700 Indian blood donors. A patient may be advised to undergo an autologous transfusion. Fortunately, the patient's procedures were uncomplicated, so a blood transfusion was unnecessary. Awareness on the part of blood bank staff regarding the variability of the blood group phenotype and the unpredictability of Anti-Inb may aid in improving patient care. To prevent further exposure, it is recommended that patients with rare antibodies carry an Antibody ID card indicating the rare antibody they possess.Inb antigen blood donors are under represented in the general donors pool. It is recommended to develop a systematic recruitment for Inb antigen donors
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1093/ajcp/aqad150.237
- https://academic.oup.com/ajcp/article-pdf/160/Supplement_1/S108/53934646/aqad150.237.pdf
- OA Status
- bronze
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4389121866
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4389121866Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1093/ajcp/aqad150.237Digital Object Identifier
- Title
-
Racial Disparity in Antibody Against A rare High Prevalence Antigen; (Anti-Inb)Work title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2023Year of publication
- Publication date
-
2023-11-01Full publication date if available
- Authors
-
M Abdelmonem, Nye Thane Ngo, W Cai, M Yunce, K Papakonstantino, C Jurado, Mrigender Virk, Juneyoung Lee, Sam S. Chang, S Yoshizuka, M CabunganList of authors in order
- Landing page
-
https://doi.org/10.1093/ajcp/aqad150.237Publisher landing page
- PDF URL
-
https://academic.oup.com/ajcp/article-pdf/160/Supplement_1/S108/53934646/aqad150.237.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
bronzeOpen access status per OpenAlex
- OA URL
-
https://academic.oup.com/ajcp/article-pdf/160/Supplement_1/S108/53934646/aqad150.237.pdfDirect OA link when available
- Concepts
-
Antigen, Antibody, Dithiothreitol, Medicine, CD44, Immunology, Chemistry, Cell, Biochemistry, EnzymeTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4389121866 |
|---|---|
| doi | https://doi.org/10.1093/ajcp/aqad150.237 |
| ids.doi | https://doi.org/10.1093/ajcp/aqad150.237 |
| ids.openalex | https://openalex.org/W4389121866 |
| fwci | 0.0 |
| type | article |
| title | Racial Disparity in Antibody Against A rare High Prevalence Antigen; (Anti-Inb) |
| biblio.issue | Supplement_1 |
| biblio.volume | 160 |
| biblio.last_page | S108 |
| biblio.first_page | S108 |
| topics[0].id | https://openalex.org/T11660 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9997000098228455 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2720 |
| topics[0].subfield.display_name | Hematology |
| topics[0].display_name | Blood groups and transfusion |
| topics[1].id | https://openalex.org/T10602 |
| topics[1].field.id | https://openalex.org/fields/13 |
| topics[1].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[1].score | 0.9898999929428101 |
| topics[1].domain.id | https://openalex.org/domains/1 |
| topics[1].domain.display_name | Life Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/1312 |
| topics[1].subfield.display_name | Molecular Biology |
| topics[1].display_name | Glycosylation and Glycoproteins Research |
| topics[2].id | https://openalex.org/T12286 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9817000031471252 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2737 |
| topics[2].subfield.display_name | Physiology |
| topics[2].display_name | Erythrocyte Function and Pathophysiology |
| is_xpac | False |
| apc_list.value | 4440 |
| apc_list.currency | USD |
| apc_list.value_usd | 4440 |
| apc_paid | |
| concepts[0].id | https://openalex.org/C147483822 |
| concepts[0].level | 2 |
| concepts[0].score | 0.6934800148010254 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q103537 |
| concepts[0].display_name | Antigen |
| concepts[1].id | https://openalex.org/C159654299 |
| concepts[1].level | 2 |
| concepts[1].score | 0.6370407342910767 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q79460 |
| concepts[1].display_name | Antibody |
| concepts[2].id | https://openalex.org/C2777824588 |
| concepts[2].level | 3 |
| concepts[2].score | 0.5491492748260498 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q414783 |
| concepts[2].display_name | Dithiothreitol |
| concepts[3].id | https://openalex.org/C71924100 |
| concepts[3].level | 0 |
| concepts[3].score | 0.5059000849723816 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[3].display_name | Medicine |
| concepts[4].id | https://openalex.org/C2780932548 |
| concepts[4].level | 3 |
| concepts[4].score | 0.4543667137622833 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q1056532 |
| concepts[4].display_name | CD44 |
| concepts[5].id | https://openalex.org/C203014093 |
| concepts[5].level | 1 |
| concepts[5].score | 0.417529821395874 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q101929 |
| concepts[5].display_name | Immunology |
| concepts[6].id | https://openalex.org/C185592680 |
| concepts[6].level | 0 |
| concepts[6].score | 0.33644771575927734 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q2329 |
| concepts[6].display_name | Chemistry |
| concepts[7].id | https://openalex.org/C1491633281 |
| concepts[7].level | 2 |
| concepts[7].score | 0.23637744784355164 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q7868 |
| concepts[7].display_name | Cell |
| concepts[8].id | https://openalex.org/C55493867 |
| concepts[8].level | 1 |
| concepts[8].score | 0.2024487555027008 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q7094 |
| concepts[8].display_name | Biochemistry |
| concepts[9].id | https://openalex.org/C181199279 |
| concepts[9].level | 2 |
| concepts[9].score | 0.1615956425666809 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q8047 |
| concepts[9].display_name | Enzyme |
| keywords[0].id | https://openalex.org/keywords/antigen |
| keywords[0].score | 0.6934800148010254 |
| keywords[0].display_name | Antigen |
| keywords[1].id | https://openalex.org/keywords/antibody |
| keywords[1].score | 0.6370407342910767 |
| keywords[1].display_name | Antibody |
| keywords[2].id | https://openalex.org/keywords/dithiothreitol |
| keywords[2].score | 0.5491492748260498 |
| keywords[2].display_name | Dithiothreitol |
| keywords[3].id | https://openalex.org/keywords/medicine |
| keywords[3].score | 0.5059000849723816 |
| keywords[3].display_name | Medicine |
| keywords[4].id | https://openalex.org/keywords/cd44 |
| keywords[4].score | 0.4543667137622833 |
| keywords[4].display_name | CD44 |
| keywords[5].id | https://openalex.org/keywords/immunology |
| keywords[5].score | 0.417529821395874 |
| keywords[5].display_name | Immunology |
| keywords[6].id | https://openalex.org/keywords/chemistry |
| keywords[6].score | 0.33644771575927734 |
| keywords[6].display_name | Chemistry |
| keywords[7].id | https://openalex.org/keywords/cell |
| keywords[7].score | 0.23637744784355164 |
| keywords[7].display_name | Cell |
| keywords[8].id | https://openalex.org/keywords/biochemistry |
| keywords[8].score | 0.2024487555027008 |
| keywords[8].display_name | Biochemistry |
| keywords[9].id | https://openalex.org/keywords/enzyme |
| keywords[9].score | 0.1615956425666809 |
| keywords[9].display_name | Enzyme |
| language | en |
| locations[0].id | doi:10.1093/ajcp/aqad150.237 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S15871148 |
| locations[0].source.issn | 0002-9173, 1943-7722 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 0002-9173 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | American Journal of Clinical Pathology |
| locations[0].source.host_organization | https://openalex.org/P4310311648 |
| locations[0].source.host_organization_name | Oxford University Press |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310311648 |
| locations[0].license | |
| locations[0].pdf_url | https://academic.oup.com/ajcp/article-pdf/160/Supplement_1/S108/53934646/aqad150.237.pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | American Journal of Clinical Pathology |
| locations[0].landing_page_url | https://doi.org/10.1093/ajcp/aqad150.237 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5021059064 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-9753-8207 |
| authorships[0].author.display_name | M Abdelmonem |
| authorships[0].countries | US |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I4210105015 |
| authorships[0].affiliations[0].raw_affiliation_string | Clinical Laboratory, Stanford Healthcare, Palo Alto , California , UNITED STATES |
| authorships[0].institutions[0].id | https://openalex.org/I4210105015 |
| authorships[0].institutions[0].ror | https://ror.org/019wqcg20 |
| authorships[0].institutions[0].type | healthcare |
| authorships[0].institutions[0].lineage | https://openalex.org/I4210105015 |
| authorships[0].institutions[0].country_code | US |
| authorships[0].institutions[0].display_name | Stanford Health Care |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | M Abdelmonem |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Clinical Laboratory, Stanford Healthcare, Palo Alto , California , UNITED STATES |
| authorships[1].author.id | https://openalex.org/A5089213639 |
| authorships[1].author.orcid | https://orcid.org/0000-0003-2419-0817 |
| authorships[1].author.display_name | Nye Thane Ngo |
| authorships[1].countries | US |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I4210105015 |
| authorships[1].affiliations[0].raw_affiliation_string | Clinical Laboratory, Stanford Healthcare, Palo Alto , California , UNITED STATES |
| authorships[1].institutions[0].id | https://openalex.org/I4210105015 |
| authorships[1].institutions[0].ror | https://ror.org/019wqcg20 |
| authorships[1].institutions[0].type | healthcare |
| authorships[1].institutions[0].lineage | https://openalex.org/I4210105015 |
| authorships[1].institutions[0].country_code | US |
| authorships[1].institutions[0].display_name | Stanford Health Care |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | N Ngo |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Clinical Laboratory, Stanford Healthcare, Palo Alto , California , UNITED STATES |
| authorships[2].author.id | https://openalex.org/A5039206567 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | W Cai |
| authorships[2].countries | US |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I4210105015 |
| authorships[2].affiliations[0].raw_affiliation_string | Clinical Laboratory, Stanford Healthcare, Palo Alto , California , UNITED STATES |
| authorships[2].institutions[0].id | https://openalex.org/I4210105015 |
| authorships[2].institutions[0].ror | https://ror.org/019wqcg20 |
| authorships[2].institutions[0].type | healthcare |
| authorships[2].institutions[0].lineage | https://openalex.org/I4210105015 |
| authorships[2].institutions[0].country_code | US |
| authorships[2].institutions[0].display_name | Stanford Health Care |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | W Cai |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Clinical Laboratory, Stanford Healthcare, Palo Alto , California , UNITED STATES |
| authorships[3].author.id | https://openalex.org/A5076814096 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | M Yunce |
| authorships[3].countries | US |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I4210105015 |
| authorships[3].affiliations[0].raw_affiliation_string | Clinical Laboratory, Stanford Healthcare, Palo Alto , California , UNITED STATES |
| authorships[3].institutions[0].id | https://openalex.org/I4210105015 |
| authorships[3].institutions[0].ror | https://ror.org/019wqcg20 |
| authorships[3].institutions[0].type | healthcare |
| authorships[3].institutions[0].lineage | https://openalex.org/I4210105015 |
| authorships[3].institutions[0].country_code | US |
| authorships[3].institutions[0].display_name | Stanford Health Care |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | M Yunce |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Clinical Laboratory, Stanford Healthcare, Palo Alto , California , UNITED STATES |
| authorships[4].author.id | https://openalex.org/A5083895275 |
| authorships[4].author.orcid | |
| authorships[4].author.display_name | K Papakonstantino |
| authorships[4].countries | US |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I4210105015 |
| authorships[4].affiliations[0].raw_affiliation_string | Clinical Laboratory, Stanford Healthcare, Palo Alto , California , UNITED STATES |
| authorships[4].institutions[0].id | https://openalex.org/I4210105015 |
| authorships[4].institutions[0].ror | https://ror.org/019wqcg20 |
| authorships[4].institutions[0].type | healthcare |
| authorships[4].institutions[0].lineage | https://openalex.org/I4210105015 |
| authorships[4].institutions[0].country_code | US |
| authorships[4].institutions[0].display_name | Stanford Health Care |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | K Papakonstantino |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Clinical Laboratory, Stanford Healthcare, Palo Alto , California , UNITED STATES |
| authorships[5].author.id | https://openalex.org/A5110648155 |
| authorships[5].author.orcid | |
| authorships[5].author.display_name | C Jurado |
| authorships[5].countries | US |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I4210105015 |
| authorships[5].affiliations[0].raw_affiliation_string | Clinical Laboratory, Stanford Healthcare, Palo Alto , California , UNITED STATES |
| authorships[5].institutions[0].id | https://openalex.org/I4210105015 |
| authorships[5].institutions[0].ror | https://ror.org/019wqcg20 |
| authorships[5].institutions[0].type | healthcare |
| authorships[5].institutions[0].lineage | https://openalex.org/I4210105015 |
| authorships[5].institutions[0].country_code | US |
| authorships[5].institutions[0].display_name | Stanford Health Care |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | C Jurado |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Clinical Laboratory, Stanford Healthcare, Palo Alto , California , UNITED STATES |
| authorships[6].author.id | https://openalex.org/A5052009256 |
| authorships[6].author.orcid | https://orcid.org/0000-0003-3232-2090 |
| authorships[6].author.display_name | Mrigender Virk |
| authorships[6].countries | US |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I4210105015 |
| authorships[6].affiliations[0].raw_affiliation_string | Clinical Laboratory, Stanford Healthcare, Palo Alto , California , UNITED STATES |
| authorships[6].institutions[0].id | https://openalex.org/I4210105015 |
| authorships[6].institutions[0].ror | https://ror.org/019wqcg20 |
| authorships[6].institutions[0].type | healthcare |
| authorships[6].institutions[0].lineage | https://openalex.org/I4210105015 |
| authorships[6].institutions[0].country_code | US |
| authorships[6].institutions[0].display_name | Stanford Health Care |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | M S Virk |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Clinical Laboratory, Stanford Healthcare, Palo Alto , California , UNITED STATES |
| authorships[7].author.id | https://openalex.org/A5100318692 |
| authorships[7].author.orcid | https://orcid.org/0000-0001-8073-9304 |
| authorships[7].author.display_name | Juneyoung Lee |
| authorships[7].countries | US |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I4210105015 |
| authorships[7].affiliations[0].raw_affiliation_string | Clinical Laboratory, Stanford Healthcare, Palo Alto , California , UNITED STATES |
| authorships[7].institutions[0].id | https://openalex.org/I4210105015 |
| authorships[7].institutions[0].ror | https://ror.org/019wqcg20 |
| authorships[7].institutions[0].type | healthcare |
| authorships[7].institutions[0].lineage | https://openalex.org/I4210105015 |
| authorships[7].institutions[0].country_code | US |
| authorships[7].institutions[0].display_name | Stanford Health Care |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | J Lee |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Clinical Laboratory, Stanford Healthcare, Palo Alto , California , UNITED STATES |
| authorships[8].author.id | https://openalex.org/A5102025364 |
| authorships[8].author.orcid | https://orcid.org/0000-0003-2066-9468 |
| authorships[8].author.display_name | Sam S. Chang |
| authorships[8].countries | US |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I4210105015 |
| authorships[8].affiliations[0].raw_affiliation_string | Clinical Laboratory, Stanford Healthcare, Palo Alto , California , UNITED STATES |
| authorships[8].institutions[0].id | https://openalex.org/I4210105015 |
| authorships[8].institutions[0].ror | https://ror.org/019wqcg20 |
| authorships[8].institutions[0].type | healthcare |
| authorships[8].institutions[0].lineage | https://openalex.org/I4210105015 |
| authorships[8].institutions[0].country_code | US |
| authorships[8].institutions[0].display_name | Stanford Health Care |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | S Chang |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Clinical Laboratory, Stanford Healthcare, Palo Alto , California , UNITED STATES |
| authorships[9].author.id | https://openalex.org/A5075772397 |
| authorships[9].author.orcid | |
| authorships[9].author.display_name | S Yoshizuka |
| authorships[9].countries | US |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I4210105015 |
| authorships[9].affiliations[0].raw_affiliation_string | Clinical Laboratory, Stanford Healthcare, Palo Alto , California , UNITED STATES |
| authorships[9].institutions[0].id | https://openalex.org/I4210105015 |
| authorships[9].institutions[0].ror | https://ror.org/019wqcg20 |
| authorships[9].institutions[0].type | healthcare |
| authorships[9].institutions[0].lineage | https://openalex.org/I4210105015 |
| authorships[9].institutions[0].country_code | US |
| authorships[9].institutions[0].display_name | Stanford Health Care |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | S Yoshizuka |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | Clinical Laboratory, Stanford Healthcare, Palo Alto , California , UNITED STATES |
| authorships[10].author.id | https://openalex.org/A5053959975 |
| authorships[10].author.orcid | |
| authorships[10].author.display_name | M Cabungan |
| authorships[10].countries | US |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I4210105015 |
| authorships[10].affiliations[0].raw_affiliation_string | Clinical Laboratory, Stanford Healthcare, Palo Alto , California , UNITED STATES |
| authorships[10].institutions[0].id | https://openalex.org/I4210105015 |
| authorships[10].institutions[0].ror | https://ror.org/019wqcg20 |
| authorships[10].institutions[0].type | healthcare |
| authorships[10].institutions[0].lineage | https://openalex.org/I4210105015 |
| authorships[10].institutions[0].country_code | US |
| authorships[10].institutions[0].display_name | Stanford Health Care |
| authorships[10].author_position | last |
| authorships[10].raw_author_name | M Cabungan |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | Clinical Laboratory, Stanford Healthcare, Palo Alto , California , UNITED STATES |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://academic.oup.com/ajcp/article-pdf/160/Supplement_1/S108/53934646/aqad150.237.pdf |
| open_access.oa_status | bronze |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Racial Disparity in Antibody Against A rare High Prevalence Antigen; (Anti-Inb) |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T11660 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9997000098228455 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2720 |
| primary_topic.subfield.display_name | Hematology |
| primary_topic.display_name | Blood groups and transfusion |
| related_works | https://openalex.org/W1965374807, https://openalex.org/W2017595667, https://openalex.org/W2101874883, https://openalex.org/W2057291091, https://openalex.org/W2049117872, https://openalex.org/W2199494561, https://openalex.org/W2412055488, https://openalex.org/W2074021765, https://openalex.org/W2167755829, https://openalex.org/W2993738004 |
| cited_by_count | 0 |
| locations_count | 1 |
| best_oa_location.id | doi:10.1093/ajcp/aqad150.237 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S15871148 |
| best_oa_location.source.issn | 0002-9173, 1943-7722 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 0002-9173 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | American Journal of Clinical Pathology |
| best_oa_location.source.host_organization | https://openalex.org/P4310311648 |
| best_oa_location.source.host_organization_name | Oxford University Press |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310311648 |
| best_oa_location.license | |
| best_oa_location.pdf_url | https://academic.oup.com/ajcp/article-pdf/160/Supplement_1/S108/53934646/aqad150.237.pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | American Journal of Clinical Pathology |
| best_oa_location.landing_page_url | https://doi.org/10.1093/ajcp/aqad150.237 |
| primary_location.id | doi:10.1093/ajcp/aqad150.237 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S15871148 |
| primary_location.source.issn | 0002-9173, 1943-7722 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 0002-9173 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | American Journal of Clinical Pathology |
| primary_location.source.host_organization | https://openalex.org/P4310311648 |
| primary_location.source.host_organization_name | Oxford University Press |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310311648 |
| primary_location.license | |
| primary_location.pdf_url | https://academic.oup.com/ajcp/article-pdf/160/Supplement_1/S108/53934646/aqad150.237.pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | American Journal of Clinical Pathology |
| primary_location.landing_page_url | https://doi.org/10.1093/ajcp/aqad150.237 |
| publication_date | 2023-11-01 |
| publication_year | 2023 |
| referenced_works_count | 0 |
| abstract_inverted_index.2 | 272 |
| abstract_inverted_index.A | 278 |
| abstract_inverted_index.O | 203 |
| abstract_inverted_index.a | 35, 143, 183, 192, 247, 257, 295, 366 |
| abstract_inverted_index.3% | 28 |
| abstract_inverted_index.An | 135 |
| abstract_inverted_index.ID | 342 |
| abstract_inverted_index.In | 18 |
| abstract_inverted_index.It | 39, 361 |
| abstract_inverted_index.NA | 252 |
| abstract_inverted_index.To | 327 |
| abstract_inverted_index.an | 92, 285, 340 |
| abstract_inverted_index.be | 281 |
| abstract_inverted_index.by | 120 |
| abstract_inverted_index.et | 21 |
| abstract_inverted_index.in | 9, 26, 42, 80, 95, 105, 167, 196, 260, 270, 323, 356 |
| abstract_inverted_index.is | 5, 34, 40, 91, 107, 332, 362 |
| abstract_inverted_index.it | 331 |
| abstract_inverted_index.of | 29, 44, 49, 56, 87, 138, 145, 194, 241, 273, 304, 311, 319 |
| abstract_inverted_index.on | 301 |
| abstract_inverted_index.so | 294 |
| abstract_inverted_index.to | 85, 114, 238, 283, 364 |
| abstract_inverted_index.(if | 246 |
| abstract_inverted_index.700 | 274 |
| abstract_inverted_index.90% | 55 |
| abstract_inverted_index.96% | 48 |
| abstract_inverted_index.AHG | 169 |
| abstract_inverted_index.All | 219 |
| abstract_inverted_index.Her | 155 |
| abstract_inverted_index.Ina | 3, 109 |
| abstract_inverted_index.Inb | 33, 111, 255, 370 |
| abstract_inverted_index.NA) | 251 |
| abstract_inverted_index.PEG | 168 |
| abstract_inverted_index.RBC | 106 |
| abstract_inverted_index.The | 60, 263 |
| abstract_inverted_index.aid | 322 |
| abstract_inverted_index.al. | 22 |
| abstract_inverted_index.all | 165, 261 |
| abstract_inverted_index.and | 11, 15, 46, 51, 54, 58, 74, 98, 110, 118, 128, 160, 176, 206, 235, 316 |
| abstract_inverted_index.are | 112, 353 |
| abstract_inverted_index.but | 102 |
| abstract_inverted_index.due | 237 |
| abstract_inverted_index.for | 150, 153, 171, 231, 369 |
| abstract_inverted_index.has | 66, 256, 267 |
| abstract_inverted_index.her | 161 |
| abstract_inverted_index.its | 103 |
| abstract_inverted_index.may | 280, 321 |
| abstract_inverted_index.out | 229 |
| abstract_inverted_index.the | 172, 180, 186, 197, 209, 215, 239, 242, 289, 302, 309, 312, 317, 345, 357 |
| abstract_inverted_index.two | 67 |
| abstract_inverted_index.was | 148, 158, 189, 298 |
| abstract_inverted_index.Arab | 12 |
| abstract_inverted_index.CD44 | 81, 90 |
| abstract_inverted_index.Case | 133, 248 |
| abstract_inverted_index.INFI | 73 |
| abstract_inverted_index.With | 212 |
| abstract_inverted_index.also | 65 |
| abstract_inverted_index.auto | 173 |
| abstract_inverted_index.bank | 306 |
| abstract_inverted_index.been | 268 |
| abstract_inverted_index.card | 343 |
| abstract_inverted_index.cell | 200, 205, 226 |
| abstract_inverted_index.from | 31, 222 |
| abstract_inverted_index.high | 70, 258 |
| abstract_inverted_index.part | 303 |
| abstract_inverted_index.rare | 7, 198, 224, 243, 264, 337, 346 |
| abstract_inverted_index.that | 83, 334 |
| abstract_inverted_index.they | 348 |
| abstract_inverted_index.this | 24, 223 |
| abstract_inverted_index.very | 6, 36, 69 |
| abstract_inverted_index.were | 227, 292 |
| abstract_inverted_index.with | 142, 164, 336 |
| abstract_inverted_index.(AET) | 127 |
| abstract_inverted_index.1973, | 19 |
| abstract_inverted_index.99.9% | 43 |
| abstract_inverted_index.Ficin | 175 |
| abstract_inverted_index.INJA. | 75 |
| abstract_inverted_index.South | 52 |
| abstract_inverted_index.Study | 249 |
| abstract_inverted_index.about | 27 |
| abstract_inverted_index.binds | 84 |
| abstract_inverted_index.blood | 62, 77, 276, 296, 305, 313, 351 |
| abstract_inverted_index.care. | 326 |
| abstract_inverted_index.carry | 339 |
| abstract_inverted_index.cell. | 244 |
| abstract_inverted_index.cells | 166, 178, 195 |
| abstract_inverted_index.donor | 199, 225 |
| abstract_inverted_index.enter | 250 |
| abstract_inverted_index.group | 63, 78, 314 |
| abstract_inverted_index.major | 220 |
| abstract_inverted_index.other | 68, 99 |
| abstract_inverted_index.pool. | 360 |
| abstract_inverted_index.ruled | 228 |
| abstract_inverted_index.staff | 307 |
| abstract_inverted_index.tumor | 100 |
| abstract_inverted_index.under | 354 |
| abstract_inverted_index.(10.6% | 14 |
| abstract_inverted_index.(DTT). | 130 |
| abstract_inverted_index.11.8%, | 16 |
| abstract_inverted_index.Arabs. | 59 |
| abstract_inverted_index.Bombay | 204 |
| abstract_inverted_index.Indian | 61, 76, 140, 275 |
| abstract_inverted_index.Report | 132 |
| abstract_inverted_index.agents | 123 |
| abstract_inverted_index.anti-S | 236 |
| abstract_inverted_index.cells, | 101, 214 |
| abstract_inverted_index.donors | 352, 359, 372 |
| abstract_inverted_index.enzyme | 116 |
| abstract_inverted_index.except | 8, 170, 230 |
| abstract_inverted_index.female | 137 |
| abstract_inverted_index.plasma | 162, 188, 216 |
| abstract_inverted_index.screen | 157 |
| abstract_inverted_index.series | 193 |
| abstract_inverted_index.study: | 134 |
| abstract_inverted_index.system | 64 |
| abstract_inverted_index.tested | 190, 217 |
| abstract_inverted_index.Antigen | 254 |
| abstract_inverted_index.Asians, | 53 |
| abstract_inverted_index.Badkere | 20 |
| abstract_inverted_index.Bombay. | 32 |
| abstract_inverted_index.Indians | 30, 50 |
| abstract_inverted_index.Iranian | 10 |
| abstract_inverted_index.Results | 245 |
| abstract_inverted_index.advised | 282 |
| abstract_inverted_index.against | 191 |
| abstract_inverted_index.anti-C, | 232 |
| abstract_inverted_index.anti-E, | 233 |
| abstract_inverted_index.anti-K, | 234 |
| abstract_inverted_index.antigen | 4, 25, 350, 371 |
| abstract_inverted_index.blacks, | 47 |
| abstract_inverted_index.bromide | 126 |
| abstract_inverted_index.descent | 141 |
| abstract_inverted_index.develop | 365 |
| abstract_inverted_index.donors. | 277 |
| abstract_inverted_index.further | 329 |
| abstract_inverted_index.general | 358 |
| abstract_inverted_index.history | 144 |
| abstract_inverted_index.matrix. | 89 |
| abstract_inverted_index.patient | 279, 325 |
| abstract_inverted_index.prevent | 328 |
| abstract_inverted_index.reacted | 163 |
| abstract_inverted_index.resides | 79 |
| abstract_inverted_index.undergo | 284 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.Anti-Inb | 320 |
| abstract_inverted_index.Antibody | 341 |
| abstract_inverted_index.In(b–) | 266 |
| abstract_inverted_index.Inb-cell | 207 |
| abstract_inverted_index.Iranians | 57 |
| abstract_inverted_index.adhesion | 93 |
| abstract_inverted_index.admitted | 149 |
| abstract_inverted_index.antibody | 156, 347 |
| abstract_inverted_index.antigen. | 38 |
| abstract_inverted_index.control. | 174 |
| abstract_inverted_index.epilepsy | 147 |
| abstract_inverted_index.function | 104 |
| abstract_inverted_index.molecule | 94 |
| abstract_inverted_index.observed | 269 |
| abstract_inverted_index.patients | 335 |
| abstract_inverted_index.surgical | 151 |
| abstract_inverted_index.unknown. | 108 |
| abstract_inverted_index.weakened | 179 |
| abstract_inverted_index.Awareness | 300 |
| abstract_inverted_index.antibody, | 185 |
| abstract_inverted_index.antigens: | 72 |
| abstract_inverted_index.destroyed | 119 |
| abstract_inverted_index.disulfide | 121 |
| abstract_inverted_index.epilepsy. | 154 |
| abstract_inverted_index.exposure, | 330 |
| abstract_inverted_index.improving | 324 |
| abstract_inverted_index.including | 202 |
| abstract_inverted_index.negative. | 218 |
| abstract_inverted_index.patient's | 187, 210, 290 |
| abstract_inverted_index.phenotype | 265, 315 |
| abstract_inverted_index.positive, | 159 |
| abstract_inverted_index.prevalent | 41 |
| abstract_inverted_index.regarding | 308 |
| abstract_inverted_index.sensitive | 113 |
| abstract_inverted_index.treatment | 152 |
| abstract_inverted_index.Caucasians | 45 |
| abstract_inverted_index.Conclusion | 253 |
| abstract_inverted_index.South-East | 139 |
| abstract_inverted_index.Suspecting | 182 |
| abstract_inverted_index.antibodies | 338 |
| abstract_inverted_index.autologous | 286 |
| abstract_inverted_index.ethnicity. | 211 |
| abstract_inverted_index.identified | 23 |
| abstract_inverted_index.indicating | 344 |
| abstract_inverted_index.inventory, | 201 |
| abstract_inverted_index.monocytes, | 97 |
| abstract_inverted_index.prevalence | 71, 259 |
| abstract_inverted_index.procedures | 291 |
| abstract_inverted_index.systematic | 367 |
| abstract_inverted_index.treatments | 117 |
| abstract_inverted_index.11-year-old | 136 |
| abstract_inverted_index.DTT-treated | 177 |
| abstract_inverted_index.considering | 208 |
| abstract_inverted_index.hyaluronate | 86 |
| abstract_inverted_index.intractable | 146 |
| abstract_inverted_index.populations | 13 |
| abstract_inverted_index.possess.Inb | 349 |
| abstract_inverted_index.proteolytic | 115 |
| abstract_inverted_index.reactivity. | 181 |
| abstract_inverted_index.recommended | 333, 363 |
| abstract_inverted_index.recruitment | 368 |
| abstract_inverted_index.represented | 355 |
| abstract_inverted_index.transfusion | 297 |
| abstract_inverted_index.variability | 310 |
| abstract_inverted_index.2-aminoethyl | 124 |
| abstract_inverted_index.Fortunately, | 288 |
| abstract_inverted_index.Inb-negative | 213 |
| abstract_inverted_index.Methods/Case | 131 |
| abstract_inverted_index.availability | 240 |
| abstract_inverted_index.glycoprotein | 82 |
| abstract_inverted_index.lymphocytes, | 96 |
| abstract_inverted_index.populations. | 262 |
| abstract_inverted_index.transfusion. | 287 |
| abstract_inverted_index.unnecessary. | 299 |
| abstract_inverted_index.Introduction: | 2 |
| abstract_inverted_index.approximately | 271 |
| abstract_inverted_index.bond-reducing | 122 |
| abstract_inverted_index.extracellular | 88 |
| abstract_inverted_index.alloantibodies | 221 |
| abstract_inverted_index.dithiothreitol | 129 |
| abstract_inverted_index.high-frequency | 184 |
| abstract_inverted_index.isothiouronium | 125 |
| abstract_inverted_index.respectively). | 17 |
| abstract_inverted_index.uncomplicated, | 293 |
| abstract_inverted_index.high-prevalence | 37 |
| abstract_inverted_index.unpredictability | 318 |
| abstract_inverted_index.Introduction/Objective | 1 |
| cited_by_percentile_year | |
| countries_distinct_count | 1 |
| institutions_distinct_count | 11 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8100000023841858 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.43212614 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |